Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
PHESGO (pertuzumab and trastuzumab) in combination with chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.